F. Rikken et R. Vos, HOW ADVERSE DRUG-REACTIONS CAN PLAY A ROLE IN INNOVATIVE DRUG RESEARCH - SIMILARITIES IN ADVERSE DRUG REACTION PROFILES OF CAPTOPRIL AND PENICILLAMINE, Pharmacy world & science, 17(6), 1995, pp. 195-200
We describe how adverse drug reactions (ADRs) can play an important ro
le in pharmaceutical research and drug development. Not only do ADRs r
epresent the risks and drawbacks associated with drugs but they can al
so be related to other knowledge available in pharmaceutical and medic
al research. We offer a model that can be used to systematically map t
he pathways through which ADRs can leas to innovative research. These
pathways include chemical, therapeutic or pathophysiological steps tha
t can be taken to arrive at new knowledge based on ADRs. We used the d
evelopment of angiotensin-converting enzyme inhibitors, especially cap
topril and penicillamine was a starting point for further innovation.
Historical analysis shows that in several instances research in the fi
eld of angiotensin-converting enzyme inhibitors has been triggered by
ADRs. The model presented here might be applicable to other areas of i
nnovative drug research.